Amicus Therapeutics to Present at Two Upcoming Investor Conferences

CRANBURY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present at two upcoming investor conferences:

Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, NV on Wednesday, May 17, 2017 at 5:00 p.m. P.T.

UBS Global Healthcare Conference 2017 in New York, NY on Monday, May 22, 2017 at 1:00 p.m. E.T.

A live webcast of both presentations can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.

Senior Director, Investor Relations

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!

Already have an account? Log in here.